Biotech IPOs: Why Values Will Increase
This article was originally published in Start Up
Executive Summary
Acquisitions and crossover investors are just beginning to push up IPO prices for the best biotech offerings, providing the first hints of real competition for shares of new issues.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007
In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for July-September 2007. Our data come from Windhover's Strategic Transactions Database.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007
In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for July-September 2007. Our data come from Windhover's Strategic Transactions Database.
Therapeutic Area Partnerships: Faster, Earlier and Make Mine Cash
The rising dealmaking value of proof of concept (POC) was the key theme at Windhover's Therapeutic Area Partnerships meeting, (Oct. 24-26, 2007). In 2002 and 2003 companies paid roughly three times the value for Phase III products that they paid for Phase II. Now, candidates at Phase II (a proxy for POC) go for about the same price as Phase III drugs. What’s going on here and what role will Big Pharma and mid-size companies find themselves playing if the trend continues?